On March 27th, "Yuhe Pharmaceutical" won a 120-billion-yuan B round of financing, led by CMB International Capital, and Materia Medica Capital. This round of financing will carry out pre-clinical research on innovative antibody drugs for users, and promote international and domestic clinical declaration of products.
"Yuhe Medicine" develops antibody drugs for tumor diseases, including macromolecular drugs such as immunological checkpoint antibodies, bispecific antibodies, and ADCs. It is said that several products have entered the stage of CMC and animal safety assessment, and it is expected to report clinical trials in 2018.
Specifically, tumor immunotherapy is one of the frontiers of cancer therapy. Generally, cancer cells can modulate the proteins of certain immune checkpoints, inhibit the killing power of T cells, and thus escape immune system surveillance. An immunological test can increase or decrease the immune signal to regulate the immune system.
In the field of treatment of tumor immunotherapy, Youhe Medicine has a variety of drugs from YH-001 to YH-008, which are in different stages of research and development.
In addition, Youhe Medicine has also developed a number of technology platforms, namely: monoclonal antibody preparation platform, in vivo drug efficacy detection platform, in vitro antibody analysis platform. These platforms use self-developed hardware and software solutions to provide a variety of related tests such as bioactivity and biochemical characterization.
Prior to this, Youhe Pharmaceutical obtained a 60-yuan A round of financing at the end of 2016, which was invested by Baiao Fortune and SDIC. In the first half of 2017, Youhe Pharmaceutical obtained a 70 million A+ round of financing, which was invested by Baiao Fortune and SDIC.
According to statistics, the global market for drugs for tumor immunotherapy has reached 46.5 billion US dollars. Domestic companies face strong foreign enemies, but they also have an advantage in terms of cost and final price. In addition, among the clinical data used by enterprises, the Chinese source accounts for a larger proportion, and the products will be more suitable for the Chinese market. According to the statistics of CICC, domestic drugs can get a market share of about 35.2 billion yuan.
Collapsible Foot Spa,Foot Spa Bath Massager,Foot Bath Spa Massager,Foot Soak Tub
Huaian Mimir Electric Appliance Co., LTD , https://www.mmfootbath.com